Monarch Capital Management Inc. Has $4.35 Million Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Monarch Capital Management Inc. decreased its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 1.8% during the 4th quarter, Holdings Channel reports. The institutional investor owned 47,079 shares of the biopharmaceutical company’s stock after selling 840 shares during the quarter. Gilead Sciences makes up approximately 1.2% of Monarch Capital Management Inc.’s investment portfolio, making the stock its 29th biggest position. Monarch Capital Management Inc.’s holdings in Gilead Sciences were worth $4,349,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently bought and sold shares of GILD. Avior Wealth Management LLC lifted its stake in shares of Gilead Sciences by 1.2% during the third quarter. Avior Wealth Management LLC now owns 9,422 shares of the biopharmaceutical company’s stock valued at $782,000 after acquiring an additional 108 shares during the period. Concord Asset Management LLC VA raised its holdings in Gilead Sciences by 3.8% during the 3rd quarter. Concord Asset Management LLC VA now owns 3,056 shares of the biopharmaceutical company’s stock worth $256,000 after purchasing an additional 111 shares during the last quarter. TFB Advisors LLC lifted its position in Gilead Sciences by 1.2% during the 3rd quarter. TFB Advisors LLC now owns 9,397 shares of the biopharmaceutical company’s stock valued at $788,000 after purchasing an additional 116 shares during the period. Sumitomo Life Insurance Co. boosted its stake in shares of Gilead Sciences by 0.7% in the 3rd quarter. Sumitomo Life Insurance Co. now owns 17,822 shares of the biopharmaceutical company’s stock valued at $1,494,000 after purchasing an additional 117 shares during the last quarter. Finally, FDx Advisors Inc. raised its stake in shares of Gilead Sciences by 2.2% during the third quarter. FDx Advisors Inc. now owns 5,365 shares of the biopharmaceutical company’s stock worth $450,000 after buying an additional 117 shares during the last quarter. 83.67% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

GILD has been the topic of several recent research reports. BMO Capital Markets raised their price target on Gilead Sciences from $94.00 to $102.00 and gave the stock an “outperform” rating in a research report on Thursday, November 7th. Morgan Stanley upgraded Gilead Sciences from an “equal weight” rating to an “overweight” rating and boosted their target price for the stock from $87.00 to $113.00 in a research report on Friday, January 10th. Robert W. Baird lifted their price objective on shares of Gilead Sciences from $80.00 to $95.00 and gave the stock a “neutral” rating in a research note on Thursday, November 7th. Daiwa America raised shares of Gilead Sciences to a “hold” rating in a research note on Monday, November 18th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Gilead Sciences in a research report on Thursday, November 7th. Eleven investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and four have given a strong buy rating to the company. According to MarketBeat.com, Gilead Sciences presently has a consensus rating of “Moderate Buy” and a consensus target price of $97.96.

Gilead Sciences Stock Up 0.2 %

Gilead Sciences stock opened at $91.84 on Friday. The company has a current ratio of 1.26, a quick ratio of 1.10 and a debt-to-equity ratio of 1.24. Gilead Sciences, Inc. has a 1-year low of $62.07 and a 1-year high of $98.90. The company has a fifty day simple moving average of $91.75 and a 200 day simple moving average of $83.97. The company has a market cap of $114.46 billion, a P/E ratio of 1,020.44, a price-to-earnings-growth ratio of 1.27 and a beta of 0.18.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, beating the consensus estimate of $1.58 by $0.44. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The company had revenue of $7.55 billion during the quarter, compared to analysts’ expectations of $7.01 billion. During the same quarter last year, the company earned $2.29 EPS. Gilead Sciences’s revenue for the quarter was up 7.0% compared to the same quarter last year. Research analysts anticipate that Gilead Sciences, Inc. will post 4.36 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Monday, December 30th. Stockholders of record on Friday, December 13th were issued a $0.77 dividend. This represents a $3.08 annualized dividend and a dividend yield of 3.35%. The ex-dividend date of this dividend was Friday, December 13th. Gilead Sciences’s payout ratio is presently 3,422.22%.

Insider Activity at Gilead Sciences

In other news, Director Jeffrey Bluestone sold 6,788 shares of Gilead Sciences stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $91.39, for a total transaction of $620,355.32. Following the completion of the transaction, the director now directly owns 8,920 shares in the company, valued at approximately $815,198.80. The trade was a 43.21 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Andrew D. Dickinson sold 248,645 shares of the company’s stock in a transaction on Friday, November 29th. The shares were sold at an average price of $92.76, for a total transaction of $23,064,310.20. Following the completion of the transaction, the chief financial officer now owns 138,919 shares in the company, valued at approximately $12,886,126.44. This represents a 64.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 456,234 shares of company stock valued at $42,130,461. 0.29% of the stock is owned by corporate insiders.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.